Bridging the translation bottleneck: China’s “Catfish Moment” for biomedical advanced technologies
-
-
REFERENCES
[1] State Council of the People's Republic of China. (2025). Regulations on the Clinical Research and Translational Application of Biomedical Advanced Technologies (Decree No. 818). https://www.mee.gov.cn/zcwj/gwywj/202510/t20251011_1129176.shtml [2] Ma X., Zhuang L., Ma W., et al. (2025). AAV9-mediated gene therapy for infantile-onset pompe's disease. N. Engl. J. Med. 392:2438−2446. DOI:10.1056/NEJMoa2407766 [3] Lv J., Wang H., Cheng X., et al. (2024). AAV1-hOTOF gene therapy for autosomal recessive deafness 9: A single-arm trial. Lancet 403:2317−2325. DOI:10.1016/S0140-6736(23)02874-X [4] National Health Commission of the People's Republic of China. (2026). Guiding Principles on the Classification of Biomedical Advanced Technologies, Pharmaceuticals, and Medical Devices (Interim). http://jingshzh.com/uploads/file/20260601/1780305729298522.pdf [5] National Health Commission of the People's Republic of China. (2026). Biomedical Advanced Technology Clinical Research Filing and Translational Application Guidelines. https://www.mee.gov.cn/zcwj/gwywj/202510/t20251011_1129176.shtml -
ABOUT THIS ARTICLE
Cite this article:
Gao J. and Gao C. (2026). Bridging the translation bottleneck: China’s “Catfish Moment” for biomedical advanced technologies. The Innovation Medicine 4:100236. https://doi.org/10.59717/j.xinn-med.2026.100236
Welcome!
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Export File
Citation
Gao J. and Gao C. (2026). Bridging the translation bottleneck: China’s “Catfish Moment” for biomedical advanced technologies. The Innovation Medicine 4:100236. https://doi.org/10.59717/j.xinn-med.2026.100236
Format
Content
DownLoad:
-
Figure 1.
Trends in proportions, sponsorship, and phases of CGT clinical trials globally and in China
